Combined Transbronchial Needle Aspiration And PET/CT For Mediastinal Staging Of Lung Cancer
description
Transcript of Combined Transbronchial Needle Aspiration And PET/CT For Mediastinal Staging Of Lung Cancer
Combined Transbronchial Needle Aspiration And PET/CT
For Mediastinal Staging Of Lung Cancer
Şermin Börekçi1, Osman Elbek1, Nazan Bayram1, Nevin Uysal1, Kemal Bakır2
1Department of Pulmonary Diseases, University of Gaziantep, School of Medicine
2 Department of Pathology, University of Gaziantep, School of Medicine
1.INTRODUCTION AND AIM-I
The most common cancer is lung cancer on the world
Lung cancer responsible for %12.8 of all cancer cases, %17.8 of all death due to cancer on the world, acording to 1999’s datasThe Turkish Thoracic Society. The guide for diagnosis and treatment of lung cancer. Thorax Journal.
2006;7(2):1-35.
1.INTRODUCTION AND AIM-II
The %70 of all lung cancer cases are at advanced (stage IV) or localy advanced stage (stage IIIA and IIIB) when diagnosed and they have no chance to surgery options for radical treatment
The Turkish Thoracic Society. The guide for diagnosis and treatment of lung cancer. Thorax Journal. 2006;7(2):1-35.
1.INTRODUCTION AND AIM-III
Staging of patient is important for;Evoluation of patient for surgery
Planning of treatment options
Determination of prognosisDetterbeck FC, DeCamp MM, Kohman LJ, Silvestri GA.
Lung cancer. Invasive staging: the guidelines. Chest 2003; 123 (suppl): 167S-75S.
1.INTRODUCTION AND AIM-IV
Procedures for mediastinal staging are clasified
into two groups as Invasive and noninvasive
Noninvasive procedures;Thorax CT, Thorax MRG, PET
İnvasive procedures;TBNA, TTNA, EUS-NA
Mediastinoscopy / Mediastinostomi, VATS
Mediastinoscopy is gold standart for mediastinal staging;
İnvasive
General anesthesia
Usually hospitalization
1.INTRODUCTION AND AIM-V
Bayram N, Borekci S, Uyar M, Bakır K and Elbek O. Transbronchial needle aspiration in the diagnosis and staging of lung cancer. Indian J Chest Dis Allied Sci 2008; 50: 273-276.
1949; Schieppati:
The first sampling from tracheal carina by using rigid bronchoscopy
1978; Wang:
Paratracheal lymph node sampling by TBNA
1979; Oho:
Using of flexible neddle with Fiberoptic bronchoscopy
1983; Wang:
Mapping and new kind of neddle for TBNA
1.INTRODUCTION AND AIM-VI
FACTORS FOR SUCCESS
Cell type of Cancer (small cell)
Right sided lesions
Large lymph nodes and masses
Localization of lesions
(paratracheal, subcarinal)
Experience Harrow E. Chest, 1991.Haponik EF. Am J Respir Crit Care Med, 1995.Harrow EM. Am J Respir Crit Care Med, 2000.
Herth FJ. Eur Respir J, 2006.
1.INTRODUCTION AND AIM-VII
A limited studies were present abouth using PET/CT instead of CT with TBNA to increase the success of TBNA.
Hsu LH, Ko JS, You DL, Liu CC, Chu NM. Respirology 2007; 12: 848-55.Bernasconi, Gambazzi F, Bubendorf L, Rasch H, Kneilfel S, Tamm M. Eur Respir J 2006; 27:
889-94.
1.INTRODUCTION AND AIM-VIII
In our study we aimed to determine;
The role of TBNA with thorax CT and PET/CT
for lung staging
The comparision with mediastinoscopy
If this approach can reduce to need for
mediastinoscopy.
2. MATERIAL AND METHODS-I
Prospective, invasive, uncontrolled study
Department of Pulmonary Diseases, University of Gaziantep
From march 2006 to March 2008The patients who suspected lung cancer
Enlarged mediastinal lymph nodes (≥1 cm) localized on CT
Underwent PET/CT scanning
Consecutive 25 patients
2. MATERIAL AND METHODS-II
TBNA sampling:Flexible bronchoscopyThorax CT and PET/CT combinationAcording to Wang’s map of lymph node 22 Gauge aspiration needle 4 sampling from each lymph node station Starting from the lymph node that the most advanced stage The other kind of sampling procedures were done after TBNA sampling
2. MATERIAL AND METHODS-III
Evaluation of samples:Adequate Sample: presence of numerous benign lymphoid cells
Negative Malignite: absence of malignant cells
Positive Malignite: presence of malignant cells
2. MATERIAL AND METHODS-IVStatistical Analysis:
Mediastinoscopy was used as “gold standart”. The sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy rate for prediction of lymph node staging of PET/CT combined TBNA were calculated.
Descriptive statistics were expressed as mean±standart deviation (SD), interquartile range (IQR) or percent (%) according to kind of data.
2. MATERIAL AND METHODS-V
Statistical Analysis:The factors that might effect positive TBNA result were analysed through logistic regression model P value less than 0.05 was deemed statistically significant.
The statistical analysis was performed using SPSS 13.0 for Windows
3.RESULTS-I
Age (year, mean±SD) 58.7±7.6 Gender Male (n,%) 25 (100) Female 0 (0)Smoking (n,%) 25 (100)Smoking (pack/year) (median, IQR) 40 (30-55)
Comorbidities (n,%) DM 2 (8) COPD 1 (4) HT 3 (12)Karnofsky performance score (mean±SD) 80.4±10.6 ECOG (mean±SD) 0.9±0.6
Characteristics of the patients
3.RESULTS-II
Clinical properties of patientsSymptoms (n,%)
cough 23 (92) increase of sputum amount 10 (40) shortness of breath 22 (88) Hemoptizi 9 (36) lack of appetite 11 (44) loss of weight (total amount/last 2 month) 11 (44) loss of weight (median±SD) 11.4±6.2 Weakness 11 (44) back pain 2 (8) chest pain 8 (32)
Paraneoplastik syndroms 1 (4) Karnofsky’s score 80.4±10.6 ECOG (median±SD) 0.9±0.6
3.RESULTS-IIIHistopathologic Diagnosis
2; 8%
23; 92%
SCCA
NSCCA
3.RESULTS-IVNSCCA
6; 26%
4; 17%10; 44%
3; 13%
NSCCA
Adenocarcinoma
Squamose cell CA
Malign epitelial CA
NS
3.RESULTS-V
Total 43 enlarged mediastinal
lymph nodes were sampled from
25 patients
3.RESULTS-VIStations of Lymph Nodes
21; 49%
13; 30%
9; 21%
Right Paratracheal
Subcarinal
Right Hilar
3.RESULTS-VIITBİA ve Mediastinoskopi Sonuçları
Lenf Nodu İstasyonu TBİA Sonucu Mediastinoskopi Sonucu1) Sağ paratrakeal negatif negatif2) Sağ paratrakeal pozitif pozitif3) Subkarinal pozitif pozitif4) Sağ hiler negatif negatif5) Sağ paratrakeal yetersiz negatif6) Subkarinal yetersiz negatif7) Sağ paratrakeal negatif negatif8) Sağ hiler yetersiz negatif9) Sağ paratrakeal yetersiz negatif10) Subkarinal yetersiz negatif11) Sağ paratrakeal negatif negatif12) Subkarinal negatif pozitif13) Sağ paratrakeal negatif örneklenmedi14) Subkarinal negatif pozitif15) Sağ hiler negatif örneklenmedi16) Sağ paratrakeal negatif negatif 17) Sağ paratrakeal yetersiz pozitif18) Sağ hiler yetersiz pozitif19) Sağ paratrakeal negatif negatif20) Sağ paratrakeal negatif negatif21) Sağ paratrakeal negatif negatif22) Subkarinal negatif negatif23) Sağ hiler negatif negatif24) Sağ paratrakeal negatif negatif25) Subkarinal negatif negatif26) Sağ hiler negatif negatif27) Subkarinal negatif negatif28) Sağparatrakeal yetersiz pozitif 29) Sağparatrakeal yetersiz pozitif30) Subkarinal yetersiz pozitif31) Sağ paratrakeal negatif negatif 32) Sağ paratrakeal pozitif yapılmadı33) Subkarinal pozitif yapılmadı34) Sağparatrakeal pozitif yapılmadı35) Subkarinal pozitif yapılmadı36) Sağ hiler pozitif yapılmadı37) Sağ paratrakeal pozitif yapılmadı38) Subkarinal pozitif yapılmadı39) Sağ hiler pozitif yapılmadı40) Sağ paratrakeal pozitif yapılmadı41) Sağ hiler pozitif yapılmadı42) Sağparatrakeal pozitif yapılmadı43) Subkarinal pozitif yapılmadı
3.RESULTS-VIIIAdequacy of sampling
33; 77%
10; 23%
Inadequate sampling
Adequate sampling
3.RESULTS-IXResults of Malignity ( positive or negative )
19; 58%
14; 42%Malignity positive
Malignity negative
3.RESULTS-XStations of lymph nodes with adequate sampling
15; 46%
10; 30%
8; 24%
Right paratracheal
Subcarinal
Right hilar
p > 0.05
3.RESULTS-XIStations of lymph nodes with malign results
6; 42%
4; 29%
4; 29%
Right paratracheal
Subcarinal
Right hilar
p > 0.05
3.RESULTS-XIIMediastinocopy
Malign Mediastinoscopy Benign
TBNA Malign 14 0 14
TBNA Benign 2 17 19
Total 16 17 33
TBNA Sensitivity %87
TBİA Specificity %100
Positive predictive value %100
Negative predictive value %89
TBNA false positivity %0
TBNA false negativity %12
3.RESULTS-XIIIThe clinical factors that might effect positive TBNA result Factor p
Lymph node location 0.18LAP on CT 0.33PET SUV Max ≥5 <0.05*Broncoscopic properties ( precence of direct or indirect findings) 0.10Adequate or inadequate TBNA sampling 0.09Tumor tissue group 0.37
* The PET SUV max≥5 was 11 times increased positive TBNA results [OR=10.68 (1.91-59.62), P<0.01
3.RESULTS-XIVThe Procedures For Diagnosis
11; 44%
10; 40%
3; 12%1; 4%
Toracotomy
Broncus mucosa biopsy
TTNAB
TBB
3.RESULTS-XVTissue diagnosis could done by TBNA for all 14 lymph node (%100) stations with malign result
The Cases With Tissue Diagnosis By TBNA
12; 86%
2; 14%
KHDAK
KHAK
3.RESULTS-XVI
The staging was completed with TBNA in 5/19 (%26) patients without mediastinoscopy.
The clinical nodal staging of patients before and after TBNA, and final surgical nodal staging after mediastinoscopy
PatientNo
Before TBNA # After TBNA After mediastinoscopy
1& T2N2M0 N2 (negative) N2 (negative)2 T4N2M0 N2 (positive) N2 (poszitive)ϯ
3& T2N2M0 N2 (negative) N2 (negative)5& T2N2M0 N2 (negative) N2 (negative)8& T2N2M0 N2 (negative) N2 (negative)9&* T2N2M0 N2 (negative) N2 (positive)
10&* T2N2M0 N2 (negative) N2 (positive) 11& T3N2M0 N2 (negative) N2 (negative)13& T2N2M0 N2 (negative) N2 (negative)14& T3N1M0 N2 (negative) N2 (negative)15& T3N2M0 N2 (negative) N2 (negative)16& T4N1M0 N2 (negative) N2 (negative)17& T4N2M0 N2 (negative) N2 (negative)20& T2N2M0 N2 (negative) N2 (negative)21 T2N2M0 N2 (positive) Initial staging was
changed after TBNA in 13/19 (%69)The correct diagnosis was done in 17/19 (%89) with TBNA
22 T3N2M0 N2 (positive)
23 T3N2M0 N2 (positive)
24 T2N2M0 N2 (positive)
25 T2N2M0 N2 (positive)
Treatments
PatientNo Treatment
1 Operation
2 Neoadjuvant chemoradiotherapy 3 Operation
4 Operation
5 Operation
6 Operation7 Operation8 Operation9 Neoadjuvant chemoradiotherapy10 Neoadjuvant chemoradiotherapy11 Operation12 CT
13 Operation14 Operation15 Operation16 Operation17 Operation18 Neoadjuvant chemoradiotherapy19 Neoadjuvant chemoradiotherapy20 Operation21 Neoadjuvant chemoradiotherapy22 CT+RT23 CT 24 Neoadjuvant chemoradiotherapy25 CT
Treatments
11; 44%
7; 28%
4; 16%
3; 12%
Operation
NeoadjuvantChemoradiotherapy
Chemoradiotherapy
Chemotherapy
4. DISCUSSION-I
TBNA could done during first broncoscopic procedure with
local anestezia, could decrease to need adding procedure
for staging so good for patient’s comfort and cost effective.
In our study staging of 5 (%26) in 19 patients were done
without mediastinoscopy and TBNA decreased the need of
mediastinoscopy.
4. DISCUSSION-IIAcording to literatures lymph node location can effect
TBNA result . Patelli and collagues showed that, TBNA sensitivity was %52 for left paratracheal, %84 for right paratracheal and %84 for subcarinal lymph node (Patelli M, et al. Ann Thoracic Surg, 2002).
In our study there is no statistical differance between
lymph node location and TBNA positivity (p>0.05).
4. DISCUSSION-III If combination of PET with TBNA increase the succes of
diagnosis is unknown. There is limited study to show that this combination is increase the succes of diagnosis (Bernasconi, et al. Eur Respir J, 2006 ve Hsu LH, et al. Respirology, 2007).
In our study the sencitivity, spesificity, PPV, NPV of the procedure that combined PET/CT with TBNA were found very high like Bernasconi’s and Hsu’s study (respectively %87, %100, %100, %89).
4.DISCUSSION-IVThe clinical factors that might effect positive TBNA result Factor p
Lymph node location 0.18LAP on CT 0.33PET SUV Max ≥5 <0.05*Broncoscopic properties ( precence of direct or indirect findings) 0.10Adequate or inadequate TBNA sampling 0.09Tumor tissue group 0.37
* The PET SUV max≥5 was 11 times increased positive TBNA results [OR=10.68 (1.91-59.62), P<0.01
4. DISCUSSION-V
In previous study tahat we done in our clinic we found that sencitivity of TBNA combined with CT were %58 (Bayram N, et al. Indian J Chest Dis Allied Sci, 2008). And also now, we found that sensitivity of of TBNA combined with PET/CT is incresed to %87. This positive result may be due to increase of TBNA experience and olso due to PET/BT that shows details.
4. DISCUSSION-VIIt is showed that TBNA combined with PET can reduce
the %57 of mediastinoscopy need (Bernasconi, et al. Eur Respir J, 2006).
In our study this ratio was %26. This lower ratio than Bernasconi’s is may be due to most of our patients were operable and toracotomy was carried out after mediastinoscopy in the same operation session.
5. LIMITATIONSThere is no control group
The distribution of lymph node station were right
There were no rapid on-site cytological examination.
6. RESULTS-I
TBNA is less invasive and has less complication than mediastinoscopy and can be used for correct staging of lung cancer.
6. RESULTS-IICombination of TBNA with PET/CT can increase sensitivity
Increse of TBNA positivity is meningfull on lymph nodes with SUV Max ≥ 5
TBNA decreased the need of mediastinoscopy
SUGGESTION
Our experience suggest that TBNA should
be routinly performed during the standart
diagnostic bronchoscopy for staging of lung
cancer to all patients with mediastinal
lympadenopathy on CT and/or PET/CT.
THANKS